Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma - Results of a pilot study

被引：11
|
作者：
Chaouche, M
Pasturaud, AL
Kamioner, D
Grandjean, M
Franiatte, J
Tourani, JM
机构：
[1] Hop Jean Bernard, Dept Oncol, F-86021 Poitiers, France
[2] Pasteur Hosp, Oncol Unit, Brest, France
[3] Laennec Hosp, Oncol Unit, Paris, France
[4] Trappes Hosp, Oncol Unit, Trappes, France
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 03期
关键词：
5-fluorouracil; immunotherapy; oxaliplatin; renal cell carcinoma;
D O I：
10.1097/00000421-200006000-00016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We report the results of a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and folinic acid in patients with metastatic renal cell carcinoma. The objective of this pilot study was to define the potential efficacy of this second-line combination in patients previously treated with interleukin-2 alone or in combination with interferon alpha. Fourteen patients with metastatic renal cell carcinoma in failure after immunotherapy were included in this trial. During treatment, patients received six chemotherapy courses (Folfox regimen) administered every 2 weeks. Each cycle combined oxaliplatin day (D) D1 and folinic acid plus 5-fluorouracil D1 and D2. At completion of treatment, no objective response was observed and two patients presented stable disease. This chemotherapy schedule in patients with metastatic renal cell carcinoma previously treated with immunotherapy does not seem to be effective.
引用
收藏
页码：288 / 289
页数：2
相关论文
共 50 条
  • [31] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    C Garufi
    E Bria
    B Vanni
    A M R Zappalà
    I Sperduti
    E Terzoli
    British Journal of Cancer, 2003, 89 : 1870 - 1875
  • [32] A phase II of oxaliplatin, 5 fluorouracil and folinic acid (modification of folfox regimen) in patients with advanced gastric cancer (CGA): Preliminary results.
    Ruiz, GC
    Blanco, CC
    Molina, JMR
    Basave, HL
    Ceron, GG
    Solis, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 374S - 374S
  • [33] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    Garufi, C
    Bria, E
    Vanni, B
    Zappalà, AMR
    Sperduti, I
    Terzoli, E
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1870 - 1875
  • [34] Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks - A feasibility study in metastatic colorectol cancer patients
    Martinez, J
    Martin, C
    Chacon, M
    Korbenfeld, E
    Bella, S
    Senna, S
    Richardet, E
    Coppola, F
    Bas, C
    Hidalgo, J
    Escobar, E
    Reale, M
    Smilovich, AM
    Wasserman, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (01): : 45 - 51
  • [35] Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
    Matteo Dalla Chiesa
    Gianluca Tomasello
    Sebastiano Buti
    Rodrigo Kraft Rovere
    Matteo Brighenti
    Silvia Lazzarelli
    Gianvito Donati
    Rodolfo Passalacqua
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 41 - 48
  • [36] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis
    Arkenau, H.
    Kubicka, S.
    Greil, R.
    Schmoll, H.
    Seufferlein, T.
    Greaven, U.
    Grothey, A.
    Kretschmar, A.
    Hinke, A.
    Porschen, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 168
  • [37] Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)
    Jung, K. H.
    Kil, S. Y.
    Choi, I. K.
    Seo, J. H.
    Shin, C.
    Kim, Y. S.
    Kim, J. H.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2006, 10 (10) : 1181 - 1182
  • [38] Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial
    Dalla Chiesa, Matteo
    Tomasello, Gianluca
    Buti, Sebastiano
    Rovere, Rodrigo Kraft
    Brighenti, Matteo
    Lazzarelli, Silvia
    Donati, Gianvito
    Passalacqua, Rodolfo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 41 - 48
  • [39] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    ANNALS OF ONCOLOGY, 2005, 16 : 283 - 283
  • [40] Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer
    Gianluca Masi
    Samanta Cupini
    Lorenzo Marcucci
    Elisa Cerri
    Fotios Loupakis
    Giacomo Allegrini
    Isa Maura Brunetti
    Elisabetta Pfanner
    Maurizio Viti
    Orlando Goletti
    Franco Filipponi
    Alfredo Falcone
    Annals of Surgical Oncology, 2006, 13 : 58 - 65
12345